Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its functions adequately. Variceal hemorrhage (bleeding from abnormal vessels in the liver called varices), Ascites (abnormal build-up of fluid in the abdomen), and Encephalopathy (brain confusion as a result of the liver not being able to get rid of toxic substances) are three symptoms of liver decompensation. The purpose of this research study is to investigate better ways to routinely monitor the condition of patients with NASH with compensated cirrhosis and to better pinpoint the development of decompensation in the livers of these patients.
This clinical research study is done to investigate better ways to routinely monitor the condition of patients with Nonalcoholic Steatohepatitis (NASH) with compensated cirrhosis. The purpose of this study is to better pinpoint the development of decompensation in the livers of these patients (some symptoms are variceal hemorrhage, ascites, and encephalopathy, defined below). NASH is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its functions adequately. Variceal hemorrhage (bleeding from abnormal vessels in the liver called varices), Ascites (abnormal build-up of fluid in the abdomen), and Encephalopathy (brain confusion as a result of the liver not being able to get rid of toxic substances) are three symptoms of liver decompensation. Aside from current routine procedures including blood draws, this study will check to see how effectively adding three additional procedures will help predict development of liver decompensation. These additional procedures are Spleen Stiffness Measurement (SSM) during a special liver ultrasound called a Fibroscan, an imagining scan called Magnetic Resonance Imagining (MRI) using a contrast agent called Gadoxetate Sodium to highlight cirrhosis, and an MRI scan called metabophenotype, which examines muscle composition of the liver.
Study Type
OBSERVATIONAL
Enrollment
240
Participants will receive the standard of care for their condition
Mayo Clinic in Rochester
Rochester, Minnesota, United States
RECRUITINGVirginia Commonwealth University
Richmond, Virginia, United States
RECRUITINGNumber of deaths
Number of deaths will be determined from death records and patient charts.
Time frame: Up to 2 years
Incidents of variceal hemorrhage
Number of participants showing bleeding from abnormal vessels in the liver called varices will be assessed using an endoscopy exam.
Time frame: Up to 2 years
Incidents of ascites
Number of participants with experiencing abnormal build-up of fluid in the abdomen will be assessed using a clinical exam including an ultrasound graded per clinical standards.
Time frame: Up to 2 years
Hepatic Encephalopathy (HE)
Number of grade 2, 3, or 4 HE events will be assessed by clinician during exams.
Time frame: Up to 2 years
Model For End-Stage Liver Disease (MELD) score
Number of participants with MELD scores greater than 15
Time frame: Up to 2 years
Hepatocellular cancer (HCC)
Number of participants with HCC
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.